Germany Syringe Market Size, Share, Opportunities, And Trends By Type, Material, Syringe Size - Forecasts From 2024 To 2029

Description

The German syringe market is expected to experience a CAGR of 3.69% throughout the forecast period, reaching a market size of US$489.542 million by 2029.

Germany Syringe Market Key Highlights:

• Strategic Transition to CDMO Pre-fillable Capabilities: A significant shift in the German market is the aggressive expansion of Contract Development and Manufacturing Organization (CDMO) services for pre-filled syringes (PFS). In October 2025, Terumo Corporation finalized the acquisition of a state-of-the-art drug product plant in Leverkusen, Germany, specifically to address the surging European demand for fill-and-finish services of polymer pre-fillable syringes and vials.
• Rising Diabetes and Cardiovascular Burden as Demand Accelerators: Chronic disease prevalence remains the primary driver of high-volume syringe procurement in Germany. With approximately 40% of fatalities in the country attributed to cardiovascular diseases and a projected rise in diabetes prevalence, the demand for specialized insulin syringes and luer-lock systems for surgical procedures is experiencing sustained upward pressure.
• Modernization of Manufacturing Infrastructure: German manufacturers are investing heavily in high-capacity, technology-driven production facilities to enhance supply chain resilience. In September 2024, Becton, Dickinson and Company (BD) announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the integration of a high-volume manufacturing line in France that increased production capacity sevenfold, directly stabilizing the supply of advanced syringes for the German healthcare sector.
• Regulatory Catalysts for Clinical Innovation: The implementation of the EU Health Technology Assessment (HTA) Regulation starting in January 2025 and the finalization of the Clinical Trials Regulation (CTR) transition have streamlined the evaluation of oncology and orphan drug treatments. These regulatory shifts directly stimulate the demand for specialized drug delivery systems, including safety-engineered and pre-filled syringes, as new therapies transition more rapidly from clinical trials to the German market.

The German syringe market serves as the cornerstone of the broader European medical device landscape, characterized by high healthcare expenditures and a robust infrastructure for both manufacturing and clinical application. This financial commitment supports a high volume of medical procedures, including over 37,200 heart bypass surgeries annually, which necessitates a steady and diverse supply of conventional and specialized syringes.

Current market dynamics are defined by a move toward advanced drug delivery systems that prioritize patient safety and dosage accuracy. The German pharmaceutical sector is increasingly adopting pre-filled syringes for biologics and mRNA-based formulations, as evidenced by significant facility investments from players like SCHOTT Pharma and Terumo. As the population ages, with one-third of the EU population expected to be over 65 by 2100, the imperative for self-administration tools and chronic disease management devices is reshaping procurement strategies across German hospitals and ambulatory care settings.

Germany Syringe Market Analysis:

Growth Drivers

The primary growth catalyst in the German syringe market is the escalating prevalence of chronic conditions, specifically diabetes and cardiovascular diseases, which require frequent and precise drug administration. The rapid expansion of the biologics and biosimilars sector further propels the demand for pre-filled syringes (PFS), as these sensitive drug profiles require the high-integrity containment provided by glass and advanced polymer materials. Additionally, Germany’s leadership in surgical procedure volume within the EU sustains a constant need for conventional and luer-lock syringes. The market also benefits from a strong focus on safety-engineered devices, driven by the imperative to reduce needlestick injuries and healthcare-associated infections among medical professionals.

Challenges and Opportunities

The stringent regulatory environment, particularly the ongoing transition to the EU Medical Device Regulation (MDR), poses significant hurdles in terms of compliance costs and administrative burdens, which can delay the introduction of new syringe technologies. Supply chain vulnerabilities for raw materials like medical-grade glass and specialized polymers also remain a concern. However, these challenges create opportunities for CDMO expansion and the localization of manufacturing. The shift toward digital integration, such as RFID-enabled syringes for inventory management, presents a lucrative growth path for manufacturers to differentiate their offerings by providing hospitals with enhanced traceability and operational efficiency.

Raw Material and Pricing Analysis

The pricing of syringes in Germany is heavily influenced by the cost of medical-grade polymers and borosilicate glass. In recent years, the market saw a shift toward high-quality pharmaceutical-grade polymers used for mRNA-based drug delivery, which commands a premium over traditional materials. Energy costs in Germany also play a critical role in the pricing of glass syringe manufacturing, which is an energy-intensive process. Manufacturers are responding by investing in modernized, energy-efficient plants, such as the SCHOTT Pharma facility in Mülheim, to mitigate these costs. Supply chain dependencies on specialized stainless steel for needles further impact the total cost of finished syringe units.

Supply Chain Analysis

The syringe supply chain in Germany is moving toward a localized and resilient model to prevent the shortages experienced in previous years. Key production hubs are located in Germany and neighbouring France, with BD and B. Braun expanding regional capacity to serve the Central European market. Logistical complexities are most pronounced in the transport and storage of pre-filled syringes, which often require cold-chain management and specialized secondary packaging to maintain sterility and drug stability. The emergence of Terumo’s CDMO base in Leverkusen represents a strategic effort to streamline the supply chain by offering "fill-and-finish" services closer to the end-user, reducing lead times for pharmaceutical companies operating in Germany.

Government Regulations

________________________________________________________________

In-Depth Segment Analysis

By Type: Insulin Syringes

The insulin syringe segment represents a critical and high-volume component of the German market, directly influenced by the nation's rising diabetes statistics. According to data from the International Diabetes Federation, the prevalence of diabetes in Germany is expected to continue its upward trajectory through 2030. This demographic shift creates a consistent and non-discretionary demand for both disposable insulin syringes and specialized injection pens. German patients are increasingly moving toward safety-engineered needles that minimize pain and reduce the risk of accidental needle sticks. This segment is characterized by high price sensitivity but also strong brand loyalty, as patients and healthcare providers prioritize devices with clear graduation marks and reliable plunger movement. Furthermore, the integration of biologic insulin analogs has increased the demand for pre-filled insulin delivery systems, which offer better dosage accuracy and ease of use for the elderly population, a demographic that is rapidly expanding in Germany.

By Material: Glass

Glass syringes, specifically those manufactured from Type I borosilicate glass, dominate the high-value segment of the German market, particularly within the prefilled syringe (PFS) category. This material is favored for its exceptional barrier properties and chemical inertness, making it indispensable for the storage and delivery of sensitive biopharmaceutical drugs and complex vaccines. As Germany continues to expand its role as a global leader in biotechnology, the demand for glass syringes is propelled by the need to ensure drug stability over extended shelf lives. The material’s ability to withstand various sterilization methods, including steam and ethylene oxide, further cements its position in the clinical sector. Despite the emergence of advanced polymers, glass remains the preferred choice for applications where the prevention of leachables and extractables is paramount. Recent investments by German companies like SCHOTT AG in specialized glass tubing for pharmaceutical packaging highlight the strategic importance of this material in maintaining the integrity of the medical supply chain.

________________________________________________________________

Competitive Environment and Analysis

The German syringe market is highly competitive, featuring a mix of domestic pioneers and global medical technology leaders. The landscape is currently defined by strategic acquisitions and capacity expansions aimed at dominating the pre-filled and safety-engineered segments.

B. Braun Melsungen AG

B. Braun Melsungen is a cornerstone of the German medical device industry, with a strategic focus on system integration and sterile processing. In its 2024 fiscal year, the group reported increased sales, driven by its "B. Braun 2030" strategy, which emphasizes efficiency and optimized structures. For the syringe market, B. Braun’s strength lies in its comprehensive infusion therapy portfolio, which includes a wide range of disposable syringes and luer-lock systems. The company has heavily invested in digital solutions and supply chain resiliency, launching a Supply Assurance Program in December 2025 to ensure uninterrupted patient care. Their positioning is focused on being a "one-stop" provider for German hospitals, combining high-quality hardware with advanced service models for the operating room and intensive care units.

Becton, Dickinson and Company (BD)

BD remains a global leader with a massive footprint in the German market, particularly in the pre-filled syringe (PFS) and safety-engineered segments. In September 2024, BD launched the BD Neopak™ XtraFlow™ Glass Prefillable Syringe, specifically designed for high-viscosity biologics. This product features an 8mm needle and thinner wall technology to reduce injection force, addressing a critical need in the growing biologics sector. BD’s competitive advantage in Germany is bolstered by its unmatched manufacturing scale and its ability to rapidly evolve its platforms to meet new therapeutic needs, such as GLP-1s and monoclonal antibodies. Their 2024 results showed strong growth, reinforcing their capacity to invest in next-generation drug delivery technologies.

________________________________________________________________

Recent Market Developments

• December 2025: B. Braun Medical Inc. launched a first-of-its-kind program to strengthen supply chain resiliency. This initiative is designed to support uninterrupted delivery of critical medical consumables, including syringes and IV solutions, to healthcare providers.
• October 2025: Terumo Corporation completed the €150 million acquisition of a drug product plant in Leverkusen, Germany. The facility provides fill-and-finish services for polymer pre-fillable syringes and vials, enhancing Terumo's CDMO responsiveness in Europe.
• September 2024: BD announced the commercial release of a new glass pre-fillable syringe, BD Neopak™ XtraFlow™, featuring thinner wall technology. This innovation reduces injection time for high-viscosity biologics, supporting the next generation of chronic disease treatments in Germany.

________________________________________________________________

Germany Syringe Market Segmentation:

• By Type:
  • Insulin Syringe
  • Conventional Syringe
  • Eccentric Tip Syringe
  • Catheter Tip Syringe
  • Luer Lock Syringe
• By Material:
  • Glass
  • Plastic
  • Stainless Steel
• By Syringe Size:
  • Smaller Volume Syringe
  • Larger Volume Syringe

Table Of Contents

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GERMANY SYRINGE MARKET BY TYPE

5.1. Introduction

5.2. Insulin Syringe

5.3. Conventional Syringe

5.3.1. Eccentric Tip Syringe

5.3.2. Catheter Tip Syringe

5.3.3. Luer Lock Syringe

6. GERMANY SYRINGE MARKET BY MATERIAL

6.1. Introduction

6.2. Glass

6.3. Plastic

6.4. Stainless Steel

7. GERMANY SYRINGE MARKET BY SYRINGE SIZE

7.1. Introduction

7.2. Smaller Volume Syringe

7.3. Larger Volume Syringe

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

9. COMPANY PROFILES

9.1. BD

9.2. B. Braun Melsungen

9.3. Terumo Europe NV

9.4. Teleflex

9.5. Nipro Europe Group Companies

9.6. ICU Medical, Inc.

9.7. Cardinal Health

LIST OF FIGURES

LIST OF TABLES

Companies Profiled

BD

B. Braun Melsungen

Terumo Europe NV

Teleflex

Nipro Europe Group Companies

ICU Medical, Inc.

Cardinal Health

Related Reports